Demographic, clinical, and treatment characteristics for the two patient cohorts
| . | . | Testing set (N = 89) . | Validation set (N = 34) . |
|---|---|---|---|
| Age | 60 (32–84) | 59 (43–81) | |
| Sex | Male | 73 (82) | 29 (85) |
| Female | 16 (18) | 5 (15) | |
| Tobacco | Yes | 57 (64) | 27 (79) |
| No | 32 (36) | 7 (21) | |
| HPV | Negative | 53 (60) | 34 (100) |
| Positive | 36 (40) | 0 (0) | |
| Overall stage | I | 3 (3) | 0 (0) |
| II | 12 (13) | 4 (12) | |
| III | 34 (38) | 8 (24) | |
| IV | 40 (46) | 22 (64) | |
| T stage | 0 | 4 (4) | 0 (0) |
| 1 | 27 (30) | 11 (32) | |
| 2 | 26 (30) | 7 (21) | |
| 3 | 15 (17) | 10 (29) | |
| 4 | 17 (19) | 6 (18) | |
| N stage | 0 | 28 (31) | 8 (24) |
| 1 | 8 (9) | 2 (6) | |
| 2 | 52 (59) | 20 (58) | |
| 3 | 1 (1) | 4 (12) | |
| Site | Oropharynx | 61 (69) | 23 (68) |
| Larynx | 21 (24) | 10 (29) | |
| Hypopharynx | 7 (7) | 1 (3) | |
| Radiation dose (Gy) | 66 (60–70) | 68 (60–72) | |
| Radiation indication | Definitive | 79 (89) | 33 (97) |
| Adjuvant | 10 (11) | 1 (3) | |
| Chemotherapy | None | 53 (60) | 19 (56) |
| Cisplatinum | 36 (40) | 15 (44) |
| . | . | Testing set (N = 89) . | Validation set (N = 34) . |
|---|---|---|---|
| Age | 60 (32–84) | 59 (43–81) | |
| Sex | Male | 73 (82) | 29 (85) |
| Female | 16 (18) | 5 (15) | |
| Tobacco | Yes | 57 (64) | 27 (79) |
| No | 32 (36) | 7 (21) | |
| HPV | Negative | 53 (60) | 34 (100) |
| Positive | 36 (40) | 0 (0) | |
| Overall stage | I | 3 (3) | 0 (0) |
| II | 12 (13) | 4 (12) | |
| III | 34 (38) | 8 (24) | |
| IV | 40 (46) | 22 (64) | |
| T stage | 0 | 4 (4) | 0 (0) |
| 1 | 27 (30) | 11 (32) | |
| 2 | 26 (30) | 7 (21) | |
| 3 | 15 (17) | 10 (29) | |
| 4 | 17 (19) | 6 (18) | |
| N stage | 0 | 28 (31) | 8 (24) |
| 1 | 8 (9) | 2 (6) | |
| 2 | 52 (59) | 20 (58) | |
| 3 | 1 (1) | 4 (12) | |
| Site | Oropharynx | 61 (69) | 23 (68) |
| Larynx | 21 (24) | 10 (29) | |
| Hypopharynx | 7 (7) | 1 (3) | |
| Radiation dose (Gy) | 66 (60–70) | 68 (60–72) | |
| Radiation indication | Definitive | 79 (89) | 33 (97) |
| Adjuvant | 10 (11) | 1 (3) | |
| Chemotherapy | None | 53 (60) | 19 (56) |
| Cisplatinum | 36 (40) | 15 (44) |
NOTE. The number of cases or mean values for the group are provided, with percent of total or range of values in parentheses.